Trials / Completed
CompletedNCT00281632
A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer
This Study is a Non-randomized, Open-label, Multi-center Phase II Study of GW786034 to Evaluate the Administration of Oral GW786034 in Subjects With Ovarian Cancer.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Female
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
This study was designed to find out how effective and safe GW786034, is in the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer that has not responded to standard treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GW786034 | 800 mg GW786034 administered orally on a daily basis. |
Timeline
- Start date
- 2006-03-01
- Primary completion
- 2008-04-01
- Completion
- 2010-10-01
- First posted
- 2006-01-25
- Last updated
- 2018-09-17
- Results posted
- 2011-01-04
Locations
10 sites across 3 countries: United States, Australia, Singapore
Source: ClinicalTrials.gov record NCT00281632. Inclusion in this directory is not an endorsement.